EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Polypharmacology guided drug repositioning approach for SARS-CoV2

Esther Jamir iD, Himakshi Sarma, Lipsa Priyadarsinee, Kikrusenuo Kiewhuo, Selvaraman Nagamani, G Narahari Sastry

PLOS ONE · 2023

DOI: 10.1371/journal.pone.0289890 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS ONE, 2023. Verfasst von Esther Jamir und 5 weiteren Autor:innen. Beteiligte Einrichtung: Advanced Computation and Data Sciences Division, CSIR-North East Institute of Science and Technology, Jorhat, Assam, India. Hauptthemen laut MEDLINE: COVID-19. Die Arbeit wurde bisher 14-mal zitiert (Crossref) und nennt 79 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Department of Biotechnology, Ministry of Science and Technology, India.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Drug repurposing has emerged as an important strategy and it has a great potential in identifying therapeutic applications for COVID-19. An extensive virtual screening of 4193 FDA approved drugs has been carried out against 24 proteins of SARS-CoV2 (NSP1-10 and NSP12-16, envelope, membrane, nucleoprotein, spike, ORF3a, ORF6, ORF7a, ORF8, and ORF9b). The drugs were classified into top 10 and bottom 10 drugs based on the docking scores followed by the distribution of their therapeutic indications. As a result, the top 10 drugs were found to have therapeutic indications for cancer, pain, neurological disorders, and viral and bacterial diseases. As drug resistance is one of the major challenges in antiviral drug discovery, polypharmacology and network pharmacology approaches were employed in the study to identify drugs interacting with multiple targets and drugs such as dihydroergotamine, ergotamine, bisdequalinium chloride, midostaurin, temoporfin, tirilazad, and venetoclax were identified among the multi-targeting drugs. Further, a pathway analysis of the genes related to the multi-targeting drugs was carried which provides insight into the mechanism of drugs and identifying targetable genes and biological pathways involved in SARS-CoV2.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

COVID-19HumansDrug RepositioningRNA, ViralProtease InhibitorsSARS-CoV-2PolypharmacologyMolecular Docking SimulationAntiviral Agents

Substanzen

RNA, ViralProtease InhibitorsAntiviral Agents

Autor:innen und Institutionen

  • Advanced Computation and Data Sciences Division, CSIR-North East Institute of Science and Technology, Jorhat, Assam, India.
  • Academy of Scientific and Innovative Research (AcSIR), Ghaziabad, India.

ORCID-Profile: Esther Jamir

Förderung

  • Department of Biotechnology, Ministry of Science and Technology, India

Zitieren

APA

Jamir, E., Sarma, H., Priyadarsinee, L., Kiewhuo, K., Nagamani, S., & Sastry, G. N. (2023). Polypharmacology guided drug repositioning approach for SARS-CoV2. PLOS ONE. https://doi.org/10.1371/journal.pone.0289890

Vancouver

Jamir E, Sarma H, Priyadarsinee L, Kiewhuo K, Nagamani S, Sastry GN. Polypharmacology guided drug repositioning approach for SARS-CoV2. PLOS ONE. 2023. doi:10.1371/journal.pone.0289890

BibTeX
@article{Jamir2023,
  author = {Jamir, Esther and Sarma, Himakshi and Priyadarsinee, Lipsa and Kiewhuo, Kikrusenuo and Nagamani, Selvaraman and Sastry, G Narahari},
  title = {Polypharmacology guided drug repositioning approach for SARS-CoV2},
  journal = {PLOS ONE},
  year = {2023},
  doi = {10.1371/journal.pone.0289890}
}
Kostenlos starten →